Skip to main content
Woman and man laughing

Can KISQALI help reduce the risk of recurrence?

In the NATALEE trial, KISQALI® (ribociclib), in combination with an aromatase inhibitor (AI), improved invasive disease-free survival (iDFS), helping to reduce the risk of recurrence vs AI alone in the broadest range of patients with stage II/III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) at high risk of recurrence; iDFS at 3 years was 90.7% for KISQALI + AI vs 87.6% for AI alone (absolute difference 3.1%; median follow-up of 33.3 months; HR=0.749 [95% CI: 0.628-0.892]). Explore the risk reduction data below.1-3

In patients with stage II/III HR+/HER2- eBC,

Over 5 years, KISQALI delivered a 28% reduction in the risk of recurrence vs AI alone

The iDFS benefit deepened over time with KISQALI + AI, beyond the 3-year treatment period

In the 3-year final analysis (median follow-up of 33.3 months)1,2:

  • iDFS at 3 years was 90.7% for KISQALI + AI vs 87.6% for AI alone (absolute difference 3.1%)

  • There was a 25.1% relative reduction in the risk of an iDFS event; HR=0.749 (95% CI: 0.628-0.892)

In an interim analysis, at a median follow-up of 28 months, a statistically significant reduction in risk was achieved despite the greater challenge of showing clinical benefit in a broad range of patients.1,3,4

NATALEE: KISQALI + AI vs AI alone at 5 years (median follow-up of 55.4 months)

KM curve of invasive disease-free survival (iDFS) at 5 years of follow-up: 85.5% with KISQALI (ribociclib) + AI vs 81.0% with AI alone in the NATALEE trial in patients with stage II/III HR+/HER2- early breast cancer (eBC) at high risk of recurrence. Over 5 years, there was a 28% reduction in risk of recurrence (iDFS); HR=0.716 (95% CI: 0.618-0.829).

Hazard ratio is based on stratified Cox model.6

iDFS was defined as the time from randomization to the date of the first event of local invasive breast cancer recurrence, regional invasive recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer (excluding basal and squamous cell carcinomas of the skin), or death (any cause).1

In the 5-year prespecified analysis5:

  • At 3 years: 2.7% absolute difference in iDFS*

  • At 5 years: 4.5% absolute difference in iDFS

  • At the time of data cutoff, only 12.4% of patients receiving KISQALI + AI had experienced an iDFS event vs 15.9% of patients treated with AI alone

  • The 5-year analysis was prespecified and descriptive in nature; as such, there was no prespecified statistical procedure controlling for type 1 error

*The difference between percentages does not equal 2.7 due to rounding.5

KISQALI can help reduce the risk of recurrence, including distant recurrence with incurable metastatic disease

NATALEE was a randomized, multicenter, open-label, phase III study of KISQALI + letrozole or anastrozole (n=2549) vs letrozole or anastrozole (n=2552) for the adjuvant treatment of men and women with stage II/III HR+/HER2- eBC, including all those with node-positive or high-risk node-negative disease (eligible stages and nodal status include: anatomic stage group IIB-III, or anatomic stage group IIA that is either node positive, or node negative with histologic grade 3, or histologic grade 2 with Ki-67 ≥20% and/or high risk by gene signature testing). iDFS was the primary end point.1,2

AI, aromatase inhibitor; eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR, hazard ratio; HR+, hormone receptor-positive; iDFS, invasive disease-free survival.

KISQALI + AI iDFS data across subgroups, including stage, nodal status, or menopausal status

 

KISQALI may be right for a variety of patients with stage II/III HR+/HER2- eBC.

Three KISQALI patients smiling

Explore the KISQALI patient profiles

Identify eligible patients like Jasmine, Erin, and Katrice today

References: 1. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp. 2. Hortobagyi GN, Lacko A, Sohn J, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol. 2025;36(2):149-157. doi:10.1016/j.annonc.2024.10.015 3. Slamon DJ, Fasching PA, Hurvitz S, et al. Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer. Ther Adv Med Oncol. 2023;15:1-16. doi:10.1177/17588359231178125 4. Fasching PA, Stroyakovskiy D, Yardley DA, et al. Ribociclib plus endocrine therapy in hormone receptor-positive/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial. JAMA Oncol. 2025;11(11):1364-1372. doi:10.1001/jamaoncol.2025.3700 5. Crown J, Stroyakovskii D, Yardley DA, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025;10(11):105858. doi:10.1016/j.esmoop.2025.105858 6. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390(12):1080-1091;(protocol). doi:10.1056/NEJMoa2305488